Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMABELZ vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Herpes simplex virus (HSV) infections: cold sores (herpes labialis),Recurrent genital herpes,Herpes zoster (shingles)
Prevention of pregnancy
100 mg orally once daily.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal half-life of 4-6 hours; clinically relevant for dosing interval of 8-12 hours in normal renal function.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily metabolized by CYP3A4. Minor contributions from CYP2C19 and CYP2D6.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Primarily renal (70-80% unchanged), with minor biliary/fecal elimination (10-15%).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Approximately 30-40%, primarily to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.2-0.3 L/kg; indicates distribution mainly into extracellular fluid.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 70-80%; intravenous: 100%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
e GFR 30-59 m L/min: 50 mg orally once daily. e GFR 15-29 m L/min: 25 mg orally once daily. e GFR <15 m L/min: not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 50 mg orally once daily. Child-Pugh Class C: not recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
<12 years: not established. ≥12 years: 100 mg orally once daily.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific adjustment; monitor renal function; consider lower doses based on creatinine clearance.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
No FDA black box warning.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor hepatic function.,Hypersensitivity reactions: Angioedema, urticaria, and anaphylaxis may occur.,Renal impairment: Dose adjustment required for moderate-to-severe renal impairment.,Carcinogenicity: No evidence in animal studies; however, long-term human data limited.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to amenamevir or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 interaction that may alter amivantamab exposure. No other specific food restrictions are known.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations, including craniofacial defects, cardiovascular anomalies, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Contraindicated during breastfeeding. M/P ratio unknown; likely excreted in human milk based on molecular weight and lipid solubility. Potential for severe adverse effects in nursing infants.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy; no dose adjustment recommended as therapy should be discontinued. If exposure occurs, immediate cessation of drug and close fetal monitoring advised.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
AMABELZ (amivantamab-vmjw) is a bispecific EGFR-MET antibody for NSCLC with EGFR exon 20 insertion mutations. Monitor for infusion-related reactions (premedicate), interstitial lung disease (hold if suspected), and venous thromboembolic events (prophylaxis recommended). Eye disorders including keratitis and uveitis occur; refer to ophthalmology if symptoms develop. Dermatologic toxicity (rash, dry skin) is common; manage with topical corticosteroids and emollients.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Do not drive or operate machinery if you experience dizziness, blurred vision, or photophobia.,Use sunscreen and protective clothing to prevent photosensitivity reactions.,Report new or worsening shortness of breath, cough, or fever immediately.,Use effective contraception during treatment and for 3 months after the last dose.,Avoid grapefruit and grapefruit juice as they may affect how the drug works.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMABELZ vs ALYACEN 1/35, answered by our medical review team.
AMABELZ is a Oral Contraceptive that works by AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMABELZ and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMABELZ is: 100 mg orally once daily.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMABELZ and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMABELZ is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations, including craniofacial defects, cardiovascular anomalies, and neural tube defects. Second an. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.